Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

OLMA

Olema Pharmaceuticals Inc

May 02 • 04:00PM ET

10.07

Dollar change -0.33
Percentage change -3.17	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWM IBB IWN LABU DFAS DFAC VTWO VFMO

Index	RUT	P/E	-	EPS (ttm)	-2.16	Insider Own	13.13%	Shs Outstand	54.99M	Perf Week	2.44%
Market Cap	563.01M	Forward P/E	-	EPS next Y	-2.66	Insider Trans	6.71%	Shs Float	48.58M	Perf Month	-9.12%
Income	-96.66M	PEG	-	EPS next Q	-0.54	Inst Own	86.70%	Short Float	18.47%	Perf Quarter	-33.97%
Sales	0.00M	P/S	-	EPS this Y	-10.16%	Inst Trans	-1.84%	Short Ratio	11.27	Perf Half Y	-24.23%
Book/sh	4.62	P/B	2.18	EPS next Y	-13.04%	ROA	-39.24%	Short Interest	8.97M	Perf Year	84.10%
Cash/sh	4.68	P/C	2.15	EPS next 5Y	-	ROE	-42.82%	52W Range	5.00 - 17.79	Perf YTD	-28.23%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-105.28%	ROI	-37.86%	52W High	-43.40%	Beta	2.10
Dividend TTM	-	Quick Ratio	12.33	Sales past 5Y	0.00%	Gross Margin	-	52W Low	101.40%	ATR (14)	0.71
Dividend Ex-Date	-	Current Ratio	12.33	EPS Y/Y TTM	17.52%	Oper. Margin	0.00%	RSI (14)	41.11	Volatility	7.43% 6.41%
Employees	74	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.10	Target Price	25.56
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	24.98%	Payout	-	Rel Volume	1.14	Prev Close	10.40
Sales Surprise	-	EPS Surprise	-1.98%	Sales Q/Q	-	Earnings	Mar 11 AMC	Avg Volume	796.58K	Price	10.07
SMA20	-4.14%	SMA50	-13.66%	SMA200	-17.17%	Trades		Volume	911,521	Change	-3.17%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-02-24	Initiated	Goldman	Buy	$24
Jan-30-24	Initiated	Citigroup	Buy	$20
Jul-21-23	Initiated	Oppenheimer	Outperform	$21
May-05-23	Initiated	CapitalOne	Overweight	$16
Feb-22-23	Initiated	Credit Suisse	Outperform	$12
Jul-06-22	Resumed	Canaccord Genuity	Buy	$16
Jun-09-22	Upgrade	H.C. Wainwright	Neutral → Buy	$12
Feb-28-22	Initiated	H.C. Wainwright	Neutral
Dec-07-21	Resumed	Cowen	Outperform
Dec-14-20	Initiated	JP Morgan	Overweight	$52
Dec-14-20	Initiated	Jefferies	Buy	$70
Dec-14-20	Initiated	Cowen	Outperform
Dec-14-20	Initiated	Canaccord Genuity	Buy	$60

Show Previous Ratings

May-01-24 07:02AM	Olema Oncology to Participate in Upcoming Investor Conferences in May (GlobeNewswire)
Apr-08-24 04:30PM	Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference (GlobeNewswire) +5.33%
Apr-05-24 12:16AM	Goldman Sachs Predicts Over 120% Rally for These 2 Strong Buy Stocks (TipRanks)
Apr-02-24 04:29PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-11-24 04:03PM	Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
07:03AM	Loading…
Mar-06-24 07:03AM	Olema Oncology Announces Publication of Data Highlighting Palazestrant's Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors (GlobeNewswire)
Mar-04-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-06-24 07:01AM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-02-24 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-22-24 10:54AM	15 Small-Cap Stocks with High Potential (Insider Monkey)
Jan-08-24 08:12AM	Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate (GlobeNewswire)
Jan-02-24 04:01PM	Olema Oncology to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-23 10:59AM	Hedge Fund and Insider Trading News: 3G Capital, Elliott Management, Harbor Capital, Three Arrows Capital, Nucor Corporation (NUE), Olema Pharmaceuticals, Inc. (OLMA), and More (Insider Monkey)
Dec-05-23 12:27PM	Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies (GlobeNewswire) -15.34%
Dec-04-23 04:29PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:30AM	Loading…
Dec-01-23 09:30AM	Top Stocks for December 2023 (Investopedia)
Nov-28-23 05:10PM	Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast Cancer Symposium (SABCS) (GlobeNewswire)
Nov-27-23 12:54PM	Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why (Zacks) -5.79%
11:32AM	This Small Cap Is My Stock Pick, as the Market Shakes Its Hangover (TheStreet.com)
Nov-22-23 09:00AM	Olema Stock Has Soared 551% This Year. Its CEO Thinks It's Still Undervalued. (Investor's Business Daily)
Nov-07-23 04:02PM	Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +10.43%
Nov-02-23 04:32PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.35%
Nov-01-23 04:27PM	Olema Oncology to Participate in Upcoming Investor Conferences in November (GlobeNewswire) +12.42%
Oct-30-23 08:50AM	Olema Pharmaceuticals, Inc. (OLMA) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Oct-26-23 10:33AM	12 Best Performing NASDAQ Stocks in 2023 (Insider Monkey)
Oct-22-23 02:55AM	Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant (GlobeNewswire)
Oct-20-23 01:15PM	5 Best Performing Biotech Stocks in 2023 (Insider Monkey)
Oct-17-23 07:01AM	Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors (GlobeNewswire)
Oct-16-23 07:02AM	Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress (GlobeNewswire) -16.55%
Oct-12-23 07:01AM	Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity (GlobeNewswire)
09:55AM	Loading…
Oct-11-23 09:55AM	Wall Street Analysts Believe Olema Pharmaceuticals, Inc. (OLMA) Could Rally 76.47%: Here's is How to Trade (Zacks) -5.18%
08:50AM	Here's Why Momentum in Olema Pharmaceuticals, Inc. (OLMA) Should Keep going (Zacks)
Oct-10-23 07:00AM	Olema Oncology Announces Expansion of Collaboration Agreement with Novartis (GlobeNewswire)
Oct-03-23 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-27-23 09:24PM	7 Strong Buy Biotech Stocks to Rejuvenate Your Portfolio (InvestorPlace)
Sep-25-23 09:55AM	Does Olema Pharmaceuticals, Inc. (OLMA) Have the Potential to Rally 80.29% as Wall Street Analysts Expect? (Zacks)
08:50AM	Here's What Could Help Olema Pharmaceuticals, Inc. (OLMA) Maintain Its Recent Price Strength (Zacks)
Sep-20-23 07:29AM	Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-15-23 01:09PM	BIOTECHNOLOGY VALUE FUND L P Acquires Stake in Olema Pharmaceuticals Inc (GuruFocus.com) +6.09%
Sep-14-23 11:02PM	Insider Buying: BIOTECHNOLOGY VALUE FUND L P Acquires 1,505,932 Shares of Olema Pharmaceuticals Inc (GuruFocus.com)
Sep-08-23 12:00PM	What Makes Olema Pharmaceuticals, Inc. (OLMA) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Predict a 91.97% Upside in Olema Pharmaceuticals, Inc. (OLMA): Here's What You Should Know (Zacks)
Sep-07-23 04:02PM	The 7 Best Small-Cap Stocks to Buy Now: September 2023 (InvestorPlace)
Sep-06-23 04:30PM	Olema Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.02%
Sep-05-23 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +19.51%
07:30AM	Olema Oncology Announces Combined Financing for Up to $180 Million (GlobeNewswire)
Aug-08-23 04:03PM	Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
08:23AM	Here's Why We're Watching Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation (Simply Wall St.)
Aug-02-23 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.05%
Aug-01-23 08:00AM	Olema Oncology to Present at the Canaccord Genuity 43rd Annual Growth Conference (GlobeNewswire)
Jul-05-23 07:30AM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-14-23 01:00PM	3 Small-Cap Biotech Stocks With Positive Momentum (TheStreet.com)
Jun-02-23 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-30-23 04:30PM	Olema Oncology to Present at the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-19-23 06:29AM	Institutional investors own a significant stake of 42% in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) (Simply Wall St.)
May-11-23 08:43AM	Olema Oncology Announces OP-1250 Continues to Demonstrate Attractive Combinability with CDK4/6 Inhibitor Palbociclib in Phase 1b/2 Study (GlobeNewswire)
May-09-23 04:01PM	Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +10.65%
May-08-23 07:06AM	Olema Oncology Announces Upcoming Poster Presentation at the 2023 ESMO Breast Cancer Annual Congress (GlobeNewswire)
May-02-23 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-13-23 04:30PM	Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference (GlobeNewswire) +7.67%
Apr-04-23 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.16%
Mar-09-23 04:00PM	Olema Oncology Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Strategic Update (GlobeNewswire)
Mar-02-23 05:00PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:05PM	Olema Oncology to Present at Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-21-23 04:30PM	Olema Oncology to Participate at Upcoming Investor Conferences (GlobeNewswire) -8.57%
Feb-02-23 06:00PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-04-23 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-03-23 07:00AM	Olema Oncology to Present at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.76%
Jan-02-23 08:23AM	We Think Olema Pharmaceuticals (NASDAQ:OLMA) Needs To Drive Business Growth Carefully (Simply Wall St.)
Dec-07-22 03:37PM	Olema Oncology Announces OP-1250 Demonstrates Attractive Combinability with CDK 4/6 Inhibitor Palbociclib in Phase 1b Dose Escalation Study (GlobeNewswire) +5.22%
Dec-02-22 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-21-22 09:16AM	Olema Oncology Announces Poster Presentations at the 2022 San Antonio Breast Cancer Symposium (SABCS) (GlobeNewswire)
Nov-08-22 04:30PM	Olema Oncology Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-22 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-01-22 08:00AM	Olema Oncology to Present at Upcoming Investor Conferences in November (GlobeNewswire)
Oct-26-22 08:01AM	Olema Pharma Says Lead Candidate Robust Activity In Breast Cancer Patients (Benzinga) +5.04%
03:00AM	Olema Oncology Announces Complete ER Antagonist OP-1250 Continues to Demonstrate Robust Activity in Phase 1/2 Clinical Trial (GlobeNewswire)
Oct-12-22 07:01AM	Olema Oncology Announces Upcoming Clinical Data Poster Presentation at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire) -5.33%
Oct-04-22 04:29PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-06-22 04:30PM	Olema Oncology to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Sep-01-22 05:01PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.58%
Aug-09-22 04:35PM	Olema Oncology Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
04:30PM	Olema Oncology Advances OP-1250 into Phase 2 Monotherapy Expansion in Patients with ER+/HER2- Advanced Breast Cancer (GlobeNewswire)
Aug-04-22 04:30PM	Olema Oncology to Present at Canaccord Genuity 42nd Annual Growth Conference (GlobeNewswire)
Aug-03-22 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.10%
Jul-26-22 07:32AM	Olema Pharmaceuticals (NASDAQ:OLMA) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jul-22-22 06:49AM	Olema (OLMA) Up on FDA Fast Track Tag for Breast Cancer Drug (Zacks) -14.44%
Jul-21-22 07:30AM	Olema Oncology Receives FDA Fast Track Designation for OP-1250 for the Treatment of ER+ / HER2- Metastatic Breast Cancer (GlobeNewswire) +20.59%
Jul-07-22 10:40AM	2 Strong Buy Penny Stocks That Could See Huge Long-Term Gains (TipRanks) +8.32%
Jul-05-22 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.18%
Jun-09-22 07:35AM	Olema Oncology Provides Clinical Update Reflecting Strong Progress Across OP-1250 Development Program (GlobeNewswire) +8.50%
07:30AM	Olema Oncology and Aurigene Announce Exclusive Collaboration and License Agreement to Discover and Develop Novel Cancer Therapies (GlobeNewswire)
Jun-02-22 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-24-22 04:30PM	Olema Oncology to Present at Jefferies Healthcare Conference (GlobeNewswire) +10.13%
May-09-22 04:30PM	Olema Oncology Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -7.62%
May-03-22 04:30PM	Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-18-22 04:30PM	Olema Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-04-22 07:30AM	Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference (GlobeNewswire) +5.37%
Mar-08-22 04:35PM	Olema Oncology Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022 (GlobeNewswire)
Feb-28-22 04:30PM	Olema Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Harmon Cyrus	Director	Mar 28 '24	Sale	10.97	20,000	219,400	826,283	Mar 29 05:00 PM
Zojwalla Naseem	CHIEF MEDICAL OFFICER	Mar 18 '24	Option Exercise	4.87	13,700	66,719	80,364	Mar 20 05:30 PM
Harmon Cyrus	Director	Feb 29 '24	Sale	12.41	25,000	310,309	846,283	Mar 04 05:30 PM
Harmon Cyrus	Director	Feb 01 '24	Sale	15.56	5,000	77,800	871,283	Feb 02 05:00 PM
Harmon Cyrus	Director	Jan 31 '24	Sale	12.23	25,000	305,750	876,283	Feb 02 05:00 PM
Zojwalla Naseem	CHIEF MEDICAL OFFICER	Jan 25 '24	Option Exercise	7.02	20,000	140,400	66,664	Jan 29 07:30 AM
Kovacs Shane William Charles	CH. OPERATING & FINANCIAL OFF.	Jan 12 '24	Option Exercise	7.02	50,000	351,000	484,987	Jan 16 07:30 AM
Harmon Cyrus	Director	Dec 29 '23	Sale	13.38	25,000	334,500	901,283	Jan 02 05:30 PM
Kovacs Shane William Charles	CH. OPERATING & FINANCIAL OFF.	Dec 12 '23	Option Exercise	7.02	10,000	70,200	434,987	Dec 12 05:55 PM
Zojwalla Naseem	CHIEF MEDICAL OFFICER	Dec 11 '23	Option Exercise	7.02	2,900	20,358	46,664	Dec 12 05:55 PM
Zojwalla Naseem	CHIEF MEDICAL OFFICER	Dec 06 '23	Option Exercise	7.02	13,100	91,962	43,764	Dec 07 08:30 PM
Paradigm Biocapital Advisors L	10% Owner	Dec 06 '23	Buy	11.60	100,000	1,160,000	6,590,981	Dec 08 04:19 PM
Graham G. Walmsley	Director	Dec 05 '23	Buy	14.19	131,870	1,871,280	1,800,000	Dec 18 06:30 PM
Harmon Cyrus	Director	Nov 30 '23	Sale	12.57	25,000	314,250	926,283	Dec 01 05:15 PM
Bohen Sean	PRESIDENT AND CEO	Nov 22 '23	Sale	13.90	27,932	388,255	144,925	Nov 22 07:00 PM
Kovacs Shane William Charles	CH. OPERATING & FINANCIAL OFF.	Nov 22 '23	Sale	13.89	9,145	127,024	424,987	Nov 22 07:00 PM
Zojwalla Naseem	CHIEF MEDICAL OFFICER	Nov 22 '23	Sale	13.89	7,095	98,550	30,664	Nov 22 07:00 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Nov 22 '23	Sale	13.89	6,653	92,410	574,099	Nov 22 07:00 PM
Harmon Cyrus	Director	Nov 22 '23	Sale	13.90	3,989	55,447	951,283	Nov 22 07:00 PM
Bohen Sean	PRESIDENT AND CEO	Nov 21 '23	Sale	14.88	29,293	435,879	172,857	Nov 22 07:00 PM
Kovacs Shane William Charles	CH. OPERATING & FINANCIAL OFF.	Nov 21 '23	Sale	14.86	9,597	142,632	434,132	Nov 22 07:00 PM
Zojwalla Naseem	CHIEF MEDICAL OFFICER	Nov 21 '23	Sale	14.84	7,461	110,747	37,759	Nov 22 07:00 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Nov 21 '23	Sale	14.88	6,976	103,823	580,752	Nov 22 07:00 PM
Harmon Cyrus	Director	Nov 21 '23	Sale	14.86	4,192	62,293	955,272	Nov 22 07:00 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Nov 08 '23	Sale	17.61	200	3,522	561,270	Nov 13 05:30 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Nov 03 '23	Sale	17.51	541	9,473	561,470	Nov 03 09:39 PM
Harmon Cyrus	Director	Nov 02 '23	Sale	15.64	5,000	78,200	943,714	Nov 02 08:50 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Nov 02 '23	Sale	15.36	3,332	51,180	562,011	Nov 03 09:39 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Nov 01 '23	Sale	15.02	6,668	100,153	565,343	Nov 03 09:39 PM
Harmon Cyrus	Director	Oct 31 '23	Sale	12.05	25,000	301,250	948,714	Nov 02 08:50 PM
Harmon Cyrus	Director	Sep 29 '23	Sale	12.41	25,000	310,250	973,714	Oct 03 05:00 PM
Myles David C.	CH. DISCOV. & NON-CLIN DEV OFF	Sep 19 '23	Sale	12.67	20,000	253,400	572,011	Sep 21 05:00 PM
BVF PARTNERS L P/IL	Director	Sep 12 '23	Buy	9.84	1,505,932	14,818,371	4,688,954	Sep 14 04:25 PM
Graham G. Walmsley	Director	Sep 12 '23	Buy	9.84	508,130	4,999,999	1,668,130	Dec 18 06:30 PM
Harmon Cyrus	Director	Sep 05 '23	Sale	11.62	10,000	116,200	998,714	Sep 05 09:08 PM
Harmon Cyrus	Director	Aug 31 '23	Sale	9.36	15,000	140,400	1,008,714	Sep 05 09:08 PM
Harmon Cyrus	Director	Aug 16 '23	Sale	10.14	15,000	152,100	1,023,714	Aug 17 05:00 PM
Harmon Cyrus	Director	Jun 08 '23	Sale	6.30	10,000	63,000	1,038,714	Jun 09 05:30 PM
Harmon Cyrus	Director	Jun 06 '23	Sale	6.29	5,000	31,475	1,048,714	Jun 07 09:30 PM
Harmon Cyrus	Director	Jun 05 '23	Sale	6.04	5,000	30,225	1,053,714	Jun 07 09:30 PM

Open in Screener

AKRO

Akero Therapeutics Inc

May 02 • 04:00PM ET

19.71

Dollar change -0.37
Percentage change -1.84	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

AKRO Akero Therapeutics Inc daily Stock Chart

Held by: VTI IWM VXF IWO IBB SCHA VTWO LABU SURI VHT

Index	RUT	P/E	-	EPS (ttm)	-2.85	Insider Own	16.42%	Shs Outstand	69.15M	Perf Week	4.12%
Market Cap	1.36B	Forward P/E	-	EPS next Y	-4.32	Insider Trans	0.25%	Shs Float	57.79M	Perf Month	-14.97%
Income	-151.76M	PEG	-	EPS next Q	-0.90	Inst Own	82.69%	Short Float	14.16%	Perf Quarter	-6.05%
Sales	0.00M	P/S	-	EPS this Y	-33.21%	Inst Trans	18.45%	Short Ratio	5.81	Perf Half Y	65.35%
Book/sh	9.60	P/B	2.05	EPS next Y	-12.11%	ROA	-32.40%	Short Interest	8.18M	Perf Year	-55.13%
Cash/sh	7.95	P/C	2.48	EPS next 5Y	-14.60%	ROE	-35.22%	52W Range	11.25 - 58.38	Perf YTD	-15.59%
Dividend Est.	-	P/FCF	-	EPS past 5Y	1.03%	ROI	-27.05%	52W High	-66.24%	Beta	-0.29
Dividend TTM	-	Quick Ratio	29.27	Sales past 5Y	0.00%	Gross Margin	-	52W Low	75.20%	ATR (14)	1.19
Dividend Ex-Date	-	Current Ratio	29.27	EPS Y/Y TTM	2.64%	Oper. Margin	0.00%	RSI (14)	35.28	Volatility	5.74% 4.83%
Employees	56	Debt/Eq	0.05	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.20	Target Price	48.89
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	-100.87%	Payout	-	Rel Volume	0.31	Prev Close	20.08
Sales Surprise	-	EPS Surprise	-19.62%	Sales Q/Q	-	Earnings	Feb 29 BMO	Avg Volume	1.41M	Price	19.71
SMA20	-7.39%	SMA50	-19.53%	SMA200	-30.70%	Trades		Volume	439,666	Change	-1.84%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-24	Resumed	BofA Securities	Neutral	$30
Sep-19-23	Initiated	Cantor Fitzgerald	Overweight	$69
Aug-28-23	Initiated	UBS	Buy	$83
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$40 → $65
Sep-14-22	Upgrade	Evercore ISI	In-line → Outperform	$10 → $50
Oct-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$27
Sep-10-21	Initiated	BofA Securities	Buy	$40
Feb-26-21	Initiated	Guggenheim	Buy	$54
Sep-10-20	Initiated	Morgan Stanley	Overweight	$70
Jul-20-20	Reiterated	H.C. Wainwright	Buy	$45 → $62
Jul-07-20	Initiated	Chardan Capital Markets	Buy	$79
Jul-01-20	Reiterated	H.C. Wainwright	Buy	$33 → $45
Mar-02-20	Initiated	H.C. Wainwright	Buy	$33
Feb-10-20	Initiated	Canaccord Genuity	Buy	$36
Jul-15-19	Initiated	ROTH Capital	Buy	$34
Jul-15-19	Initiated	JP Morgan	Overweight	$28
Jul-15-19	Initiated	Jefferies	Buy	$28
Jul-15-19	Initiated	Evercore ISI	Outperform	$35

Show Previous Ratings

Apr-30-24 08:00AM	Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer (GlobeNewswire)
Apr-22-24 06:00AM	6 Stocks Positioned to Soar as Investors Focus on MASH (News Direct)
Mar-20-24 01:32PM	Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks (Insider Monkey)
12:58PM	AKRO Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Akero Therapeutics (NASDAQ:AKRO) (GlobeNewswire)
Mar-18-24 07:00AM	Ozempic Cant Do It AllA Potential New Blockbuster Is a Reminder of That (The Wall Street Journal)
04:02PM	Loading…
Mar-08-24 04:02PM	Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Mar-07-24 04:01PM	Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology (GlobeNewswire)
Mar-06-24 11:54PM	President and CEO Andrew Cheng Sells 75,000 Shares of Akero Therapeutics Inc (AKRO) (GuruFocus.com)
Mar-05-24 09:13PM	Akero Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
02:12PM	Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study (Zacks)
Mar-04-24 04:21PM	Akero Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +11.72%
04:04PM	Why Akero Rocketed And Pulled Rival 89bio Higher On Results In Liver Disease Treatment (Investor's Business Daily)
12:30PM	Data Suggests Makers of Fatty Liver Treatments Wont Be Displaced by Obesity Drugs (The Wall Street Journal)
11:59AM	Akero Therapeutics Bats Back Challenge From Lilly in Emerging Liver-Drug Market (Barrons.com)
09:23AM	Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment (Investor's Business Daily)
06:22AM	Loading…
06:22AM	UPDATE 1-Akero's lead drug helps reduce scarring in fatty liver disease patients (Reuters)
06:09AM	Akero's lead drug helps improve scarring in fatty liver disease patients (Reuters)
06:00AM	Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study (GlobeNewswire)
04:00AM	Akero strengthens MASH drugs case with new study data (BioPharma Dive)
Mar-01-24 09:55AM	Wall Street Analysts Predict a 58.87% Upside in Akero Therapeutics, Inc. (AKRO): Here's What You Should Know (Zacks)
Feb-29-24 08:00AM	Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH (GlobeNewswire)
07:00AM	Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-06-24 10:48AM	Cramer's Stop Trading: Akero Therapeutics (CNBC TV) -12.25%
Feb-05-24 09:55AM	Here's Why Akero Therapeutics, Inc. (AKRO) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Jan-30-24 09:40AM	Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year? (Zacks) -5.22%
Jan-03-24 08:15AM	Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.41%
Dec-18-23 07:00AM	Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program (GlobeNewswire)
Dec-13-23 03:06AM	Insider Sell Alert: Akero Therapeutics Inc's President and CEO Andrew Cheng Disposes of 26,978 ... (GuruFocus.com)
Dec-05-23 01:34PM	12 Most Promising Stocks to Buy According to Hedge Funds (Insider Monkey)
12:36PM	Hedge Fund and Insider Trading News: Jeff Ubben, Bill Ackman, Saba Capital Management, Akero Therapeutics Inc (AKRO), Verizon Communications Inc. (VZ) and More (Insider Monkey)
07:21PM	Loading…
Nov-14-23 07:21PM	Akero Therapeutics Inc (AKRO) Reports Q3 2023 Financial Results (GuruFocus.com)
Nov-13-23 07:00AM	Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-10-23 08:57AM	Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD's The Liver Meeting 2023 (GlobeNewswire)
Nov-08-23 07:00AM	Akero Therapeutics to Present at Upcoming Healthcare Conferences in November (GlobeNewswire)
Oct-17-23 04:05PM	Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference (GlobeNewswire)
Oct-12-23 04:38PM	Why Akero Therapeutics Shares Are Slumping This Week (Motley Fool)
08:24AM	Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback (Zacks)
Oct-11-23 05:35PM	Akero Therapeutics' Lead Candidate Potential: Analyst Unpacks Complicated Regulatory Path Forward (Benzinga) -17.13%
11:11AM	Akero (AKRO) Slumps 63% on Mixed Results From NASH Study (Zacks)
Oct-10-23 04:13PM	Why Shares of 89bio Plummeted on Tuesday (Motley Fool) -62.61%
04:03PM	Why Akero Therapeutics Lost More Than Half Its Value And Dragged Down 89bio (Investor's Business Daily)
12:10PM	PepsiCo, Palantir rise; Neogen, Akero Therapeutics fall, Tuesday, 10/10/2023 (Associated Press Finance)
11:44AM	Why Akero Therapeutics Stock Is Crashing Today (Motley Fool)
10:37AM	Akero Therapeutics, Palantir, Hyatt Hotels: Trending tickers (Yahoo Finance Video)
09:29AM	Why Is Akero Therapeutics (AKRO) Stock Down 58% Today? (InvestorPlace)
07:15AM	Akero's drug for fatty liver disease misses main trial goal (Reuters)
07:00AM	Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins (GlobeNewswire)
Oct-09-23 04:05PM	Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH (GlobeNewswire)
Oct-05-23 07:01AM	Insider Sell: Akero Therapeutics Inc CEO Andrew Cheng Sells 25,000 Shares (GuruFocus.com)
Oct-04-23 08:00AM	Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology (GlobeNewswire)
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Sep-27-23 09:24PM	7 Strong Buy Biotech Stocks to Rejuvenate Your Portfolio (InvestorPlace)
Sep-14-23 07:56AM	Madrigal (MDGL) Gains on NDA for NASH Therapy Acceptance by FDA (Zacks)
Aug-31-23 07:00AM	Akero Therapeutics to Present at Upcoming Healthcare Conferences in September (GlobeNewswire)
Aug-28-23 07:00AM	Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023 (GlobeNewswire)
Aug-11-23 06:00AM	Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +6.59%
Jul-11-23 09:02AM	Infinity Pharma (INFI) Stock Up on Advancing Cancer Study (Zacks)
Jul-10-23 09:32AM	Viking Therapeutics (VKTX) Surges 64% Year to Date: Here's Why (Zacks)
09:29AM	Sotherly Hotels' (SOHO) Q2 Operating Trend Reflects Solid Demand (Zacks)
08:58AM	Axsome (AXSM) Doses First Patient in Late-Stage ADHD Study (Zacks)
Jul-07-23 08:00AM	Obesity Drugs Wont Starve These Other Potential Blockbusters (The Wall Street Journal)
07:46AM	Ultragenyx (RARE) Doses First Patients in Bone Disease Studies (Zacks)
Jul-03-23 11:20AM	Baudax Bio (BXRX) Up 125% on Acquiring TeraImmune (Zacks)
10:25AM	Alnylam (ALNY) Announces FDA Committee Onpattro sNDA Review Date (Zacks)
Jul-01-23 09:00AM	Top Stocks for July 2023 (Investopedia)
Jun-29-23 10:04AM	Esperion (ESPR) to Expand Nilemdo and Nustendi Label in Europe (Zacks)
09:59AM	Axsome (AXSM) Down on Public Offering of Common Stock (Zacks)
09:18AM	Reata's (RETA) Skyclarys PAS Gets FDA Nod, Stock Rises 7% (Zacks)
Jun-28-23 10:53AM	Amicus (FOLD) Gets Approval in Europe for Pompe Disease Drug (Zacks)
Jun-27-23 01:47PM	Agios' (AGIO) Sickle Cell Disease Study Meets Primary Endpoint (Zacks)
Jun-26-23 11:23AM	AbbVie (ABBV) Gets CHMP Positive Opinion for Atogepant Approval (Zacks) -9.17%
11:15AM	Novo Nordisk (NVO) Posts Upbeat Once-Weekly Insulin Icodec Data (Zacks)
10:36AM	Amylyx (AMLX) Down on Negative CHMP Opinion for ALS candidate (Zacks)
08:50AM	Recent Price Trend in Akero Therapeutics, Inc. (AKRO) is Your Friend, Here's Why (Zacks)
08:21AM	Pfizer's (PFE) Litfulo Receives FDA Nod for Alopecia Areata (Zacks)
06:41AM	Daily Vickers Top Buyers & Sellers for 06/26/2023 (Argus Research)
Jun-23-23 10:50AM	Pieris (PIRS) Declines as AZN Halts Study of Asthma Candidate (Zacks)
09:15AM	Horizon's (HZNP) Tepezza Study in Japan for TED Meets Goal (Zacks)
07:00AM	Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology (GlobeNewswire)
Jun-22-23 09:18AM	Alderya (ALDX) Stock Declines on Getting CRL for PVRL Candidate (Zacks)
Jun-21-23 03:21PM	Denali (DNLI) Provides Update on Hunter Syndrome Study (Zacks)
10:46AM	Merck's (MRK) Gastric Cancer Study Fails to Meet a Primary Goal (Zacks)
Jun-20-23 08:54AM	Verve (VERV) Up 9.9% in a Week on Collaboration With Eli Lilly (Zacks)
Jun-19-23 10:28AM	Reata (RETA) Announces FDA's Acceptance of Skyclarys PAS (Zacks)
10:18AM	GSK Announces Extension of FDA Review for Rare Blood Therapy (Zacks)
Jun-16-23 10:26AM	Aldeyra (ALDX) Up On Positive Data From Conjunctivitis Study (Zacks)
08:39AM	Iovance (IOVA) Updates on Combo Drug in Advanced Melanoma Study (Zacks)
Jun-15-23 09:43AM	Lava (LVTX) Discontinues Hematological Tumor Study, Shares Fall (Zacks)
08:18AM	IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study (Zacks)
Jun-14-23 12:17PM	Can-Fite (CANF) Up on Namodenoson Progress in Pancreatic Cancer (Zacks)
11:48AM	Recursion (RXRX) Up on Completing REC-994 Study Enrollment (Zacks)
09:26AM	Acadia (ACAD) to Begin Study on ACP-101 for Hyperphagia in PWS (Zacks)
Jun-13-23 10:14AM	AstraZeneca (AZN) Breast Cancer Combo Drug Gets Priority Review (Zacks)
09:40AM	Is Akero Therapeutics (AKRO) Outperforming Other Medical Stocks This Year? (Zacks)
09:18AM	Ironwood (IRWD), AbbVie Get FDA Nod for Linzess Label Expansion (Zacks)
Jun-12-23 10:00AM	Editas (EDIT) Posts Upbeat Initial Data From SCD & TDT Studies (Zacks) +5.43%
09:48AM	AstraZeneca (AZN) & Quell to Co-Develop Autoimmune Cell Therapies (Zacks)
Jun-08-23 11:49AM	Timber (TMBR) Surges on Carcinogenicity Waiver for TMB-001 (Zacks)
11:20AM	AVITA (RCEL) Gets FDA Nod for Expanded Use of RECELL System (Zacks)
Jun-07-23 12:31PM	Alkermes (ALKS) Gets Final Award in Janssen Arbitration, Ups View (Zacks)

Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Young Jonathan	Chief Operating Officer	Apr 01 '24	Sale	24.38	5,000	121,913	263,306	Apr 03 06:55 PM
Cheng Andrew	President and CEO	Mar 13 '24	Sale	28.33	1,969	55,782	589,447	Mar 15 04:43 PM
White William Richard	Chief Financial Officer	Mar 13 '24	Sale	28.33	724	20,511	49,630	Mar 15 04:44 PM
Yale Catriona	Chief Development Officer	Mar 13 '24	Sale	28.33	723	20,483	77,692	Mar 15 04:45 PM
Young Jonathan	Chief Operating Officer	Mar 13 '24	Sale	28.33	651	18,443	268,306	Mar 15 04:42 PM
Rolph Timothy	Chief Scientific Officer	Mar 13 '24	Sale	28.33	619	17,536	182,558	Mar 15 04:42 PM
Cheng Andrew	President and CEO	Mar 04 '24	Option Exercise	17.17	75,000	1,288,062	666,416	Mar 06 08:14 PM
Yale Catriona	Chief Development Officer	Mar 04 '24	Option Exercise	13.96	20,646	288,124	99,061	Mar 06 08:13 PM
Cheng Andrew	President and CEO	Mar 04 '24	Sale	32.87	75,000	2,465,063	591,416	Mar 06 08:14 PM
Yale Catriona	Chief Development Officer	Mar 04 '24	Sale	35.49	20,646	732,727	78,415	Mar 06 08:13 PM
Young Jonathan	Chief Operating Officer	Mar 01 '24	Option Exercise	0.61	83,321	51,242	268,957	Mar 05 05:16 PM
Cheng Andrew	President and CEO	Jan 02 '24	Option Exercise	0.61	40,000	24,600	590,911	Jan 03 05:00 PM
Young Jonathan	Chief Operating Officer	Dec 27 '23	Option Exercise	6.36	5,414	34,433	190,545	Dec 29 08:30 PM
Young Jonathan	Chief Operating Officer	Dec 27 '23	Sale	24.00	5,414	129,936	185,131	Dec 29 08:30 PM
Cheng Andrew	President and CEO	Dec 14 '23	Sale	20.76	1,628	33,797	550,911	Dec 18 08:37 PM
White William Richard	Chief Financial Officer	Dec 14 '23	Sale	20.76	611	12,684	50,354	Dec 18 08:40 PM
Yale Catriona	Chief Development Officer	Dec 14 '23	Sale	20.76	597	12,394	77,910	Dec 18 08:49 PM
Young Jonathan	Chief Operating Officer	Dec 14 '23	Sale	20.76	543	11,273	185,131	Dec 18 08:39 PM
Rolph Timothy	Chief Scientific Officer	Dec 14 '23	Sale	20.76	514	10,671	182,672	Dec 18 08:29 PM
Cheng Andrew	President and CEO	Dec 11 '23	Option Exercise	6.36	7,405	47,096	559,944	Dec 11 08:59 PM
Cheng Andrew	President and CEO	Dec 11 '23	Sale	20.02	7,405	148,273	552,539	Dec 11 08:59 PM
Cheng Andrew	President and CEO	Dec 08 '23	Option Exercise	6.36	12,873	81,872	473,871	Dec 11 08:59 PM
Graham G. Walmsley	Director	Dec 08 '23	Buy	19.83	100,000	1,982,940	800,000	Dec 11 09:06 PM
Cheng Andrew	President and CEO	Dec 08 '23	Sale	20.01	12,873	257,571	460,998	Dec 11 08:59 PM
Cheng Andrew	President and CEO	Dec 07 '23	Option Exercise	6.36	6,700	42,612	467,698	Dec 11 08:59 PM
Cheng Andrew	President and CEO	Dec 07 '23	Sale	20.02	6,700	134,125	460,998	Dec 11 08:59 PM
Graham G. Walmsley	Director	Dec 01 '23	Buy	16.99	50,000	849,730	700,000	Dec 05 08:37 AM
Graham G. Walmsley	Director	Nov 30 '23	Buy	16.90	50,000	844,835	650,000	Dec 05 08:37 AM
Young Jonathan	Chief Operating Officer	Nov 17 '23	Sale	14.68	30,000	440,259	153,177	Nov 21 05:30 PM
Cheng Andrew	President and CEO	Oct 02 '23	Option Exercise	6.36	25,000	159,000	485,998	Oct 04 08:41 PM
Young Jonathan	Chief Operating Officer	Oct 02 '23	Option Exercise	21.10	490	10,339	183,667	Oct 04 08:33 PM
Cheng Andrew	President and CEO	Oct 02 '23	Sale	47.91	25,000	1,197,827	460,998	Oct 04 08:41 PM
Young Jonathan	Chief Operating Officer	Oct 02 '23	Sale	51.10	490	25,039	183,177	Oct 04 08:33 PM
Yale Catriona	Chief Development Officer	Sep 21 '23	Option Exercise	6.36	5,000	31,800	51,010	Sep 25 08:31 PM
Yale Catriona	Chief Development Officer	Sep 21 '23	Sale	48.07	5,000	240,356	46,010	Sep 25 08:31 PM
Graham G. Walmsley	Director	Sep 19 '23	Buy	26.00	400,000	10,400,000	400,000	May 23 09:55 PM
Cheng Andrew	President and CEO	Sep 13 '23	Sale	50.34	1,682	84,672	460,998	Sep 25 08:36 PM
White William Richard	Chief Financial Officer	Sep 13 '23	Sale	50.34	632	31,815	18,468	Sep 25 08:31 PM
Yale Catriona	Chief Development Officer	Sep 13 '23	Sale	50.34	617	31,060	46,010	Sep 25 08:31 PM
Young Jonathan	Chief Operating Officer	Sep 13 '23	Sale	50.34	562	28,291	183,177	Sep 25 08:28 PM
Rolph Timothy	Chief Scientific Officer	Sep 13 '23	Sale	50.34	531	26,731	150,689	Sep 25 08:30 PM
Cheng Andrew	President and CEO	Sep 01 '23	Option Exercise	6.36	25,000	159,000	487,680	Sep 18 06:48 PM
Cheng Andrew	President and CEO	Sep 01 '23	Sale	49.77	25,000	1,244,248	462,680	Sep 18 06:48 PM
Cheng Andrew	President and CEO	Aug 30 '23	Option Exercise	0.61	15,000	9,225	462,680	Aug 30 07:04 PM
Yale Catriona	Chief Development Officer	Aug 28 '23	Option Exercise	6.36	5,745	36,538	52,372	Aug 30 07:04 PM
Yale Catriona	Chief Development Officer	Aug 28 '23	Sale	49.99	5,745	287,191	46,627	Aug 30 07:04 PM
Graham G. Walmsley	Director	Aug 08 '23	Buy	42.06	25,000	1,051,475	600,000	Aug 10 04:46 PM
Cheng Andrew	President and CEO	Aug 01 '23	Option Exercise	6.36	25,000	159,000	472,680	Aug 03 04:13 PM
Graham G. Walmsley	Director	Aug 01 '23	Buy	43.26	25,000	1,081,525	575,000	Aug 01 07:52 PM
Cheng Andrew	President and CEO	Aug 01 '23	Sale	43.15	25,000	1,078,867	447,680	Aug 03 04:13 PM
Graham G. Walmsley	Director	Jul 28 '23	Buy	42.69	30,000	1,280,709	550,000	Aug 01 07:52 PM
Cheng Andrew	President and CEO	Jul 03 '23	Option Exercise	6.36	25,000	159,000	472,680	Jul 06 08:44 PM
Cheng Andrew	President and CEO	Jul 03 '23	Sale	44.88	25,000	1,122,041	447,680	Jul 06 08:44 PM
Cheng Andrew	President and CEO	Jun 27 '23	Option Exercise	0.61	40,000	24,600	447,680	Jun 27 07:12 PM
Yale Catriona	Chief Development Officer	Jun 23 '23	Sale	50.76	11,000	558,360	46,627	Jun 23 08:06 PM
Yale Catriona	Chief Development Officer	Jun 22 '23	Sale	52.18	11,000	573,935	57,627	Jun 23 08:06 PM
Yale Catriona	Chief Development Officer	Jun 21 '23	Sale	52.26	11,349	593,095	68,627	Jun 23 08:06 PM
White William Richard	Chief Financial Officer	Jun 20 '23	Option Exercise	7.01	17,500	122,658	39,877	Jun 22 05:20 PM
White William Richard	Chief Financial Officer	Jun 20 '23	Sale	55.00	20,777	1,142,735	19,100	Jun 22 05:20 PM
Heyman Tomas J.	Director	Jun 16 '23	Option Exercise	25.04	26,000	651,040	26,000	Jun 21 05:54 PM
Henderson Jane	Director	Jun 16 '23	Option Exercise	7.01	40,000	280,400	40,000	Jun 21 05:47 PM
Rolph Timothy	Chief Scientific Officer	Jun 16 '23	Option Exercise	0.61	40,000	24,400	229,420	Jun 21 05:46 PM
Rolph Timothy	Chief Scientific Officer	Jun 16 '23	Sale	54.78	78,200	4,284,066	151,220	Jun 21 05:46 PM
Henderson Jane	Director	Jun 16 '23	Sale	54.17	40,000	2,166,685	0	Jun 21 05:47 PM
Heyman Tomas J.	Director	Jun 16 '23	Sale	54.67	26,000	1,421,529	0	Jun 21 05:54 PM
Cheng Andrew	President & CEO	Jun 13 '23	Sale	55.16	1,613	88,973	407,680	Jun 15 09:38 PM
White William Richard	Chief Financial Officer	Jun 13 '23	Sale	55.16	606	33,427	22,377	Jun 15 09:41 PM
Yale Catriona	Chief Development Officer	Jun 13 '23	Sale	55.16	591	32,600	79,976	Jun 15 09:29 PM
Young Jonathan	Chief Operating Officer	Jun 13 '23	Sale	55.16	538	29,676	183,739	Jun 15 09:35 PM
Rolph Timothy	Chief Scientific Officer	Jun 13 '23	Sale	55.16	509	28,076	189,420	Jun 15 09:35 PM
Cheng Andrew	President and CEO	Jun 01 '23	Option Exercise	1.46	25,000	36,459	434,293	Jun 05 06:23 PM
Cheng Andrew	President and CEO	Jun 01 '23	Sale	45.10	25,000	1,127,430	409,293	Jun 05 06:23 PM
Graham G. Walmsley	Director	May 19 '23	Buy	42.00	120,000	5,040,000	520,000	May 23 09:55 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

OLMA

Olema Pharmaceuticals Inc

AKRO

Akero Therapeutics Inc

Upgrade your FINVIZ experience